Literature DB >> 28539214

Validation of the Eighth Edition of the TNM Staging System for Lung Cancer in 2043 Surgically Treated Patients With Non-small-cell Lung Cancer.

Kezhong Chen1, Haiqing Chen1, Fan Yang1, Xizhao Sui1, Xiao Li1, Jun Wang2.   

Abstract

PURPOSE: The International Association for the Study of Lung Cancer has proposed a revision of the Tumor, Node, Metastasis (TNM) classification for lung cancer. The purpose of this study is to evaluate the prognostic value of the eighth edition of the TNM staging system in surgically treated patients with non-small-cell lung cancer.
METHODS: Data from 2043 consecutive patients with non-small-cell lung cancer who underwent surgical treatment in our single center between January 2006 and September 2015 were collected and analyzed retrospectively. Cox proportional hazard models were used to assess the prognostic significance of the T and N descriptors.
RESULTS: The reversed overall survival curves of stage IIA and stage IIB in the seventh edition were corrected in the eighth edition. Better prognostic value in predicting overall survival, including a higher log rank test of trend χ2 statistic (433.6 vs. 414.2), a smaller Akaike Information Criterion value (4759.6 vs. 4768.2), a higher Harrell C-index (0.776 vs. 0.769), and a lower integrated Brier score (0.092 vs. 0.093), was observed for the eighth edition relative to the seventh edition. Recurrence-free survival analysis of subsets of patients stratified by T and N descriptors showed a stepwise deterioration. Significant differences were found between patients of subdivided stage IA (IAI vs. IA2; P = .003 and IA2 vs. IA3; P = .004).
CONCLUSION: The eighth edition of the TNM staging system for lung cancer has prognostic value superior to that of the seventh edition. It was able to predict recurrence-free survival well.
Copyright © 2017 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Overall survival; Prognostic value; Recurrence-free survival; Survival analyses; TNM classification

Mesh:

Year:  2017        PMID: 28539214     DOI: 10.1016/j.cllc.2017.04.001

Source DB:  PubMed          Journal:  Clin Lung Cancer        ISSN: 1525-7304            Impact factor:   4.785


  11 in total

1.  Comment on an external validation of the 8th edition of the TNM classification for lung cancer staging in patients treated with chemoradiation.

Authors:  Ramón Palmero; Arturo Navarro-Martin; Ernest Nadal
Journal:  Ann Transl Med       Date:  2019-07

2.  Validation of the 8th edition of the TNM staging system in 3,950 patients with surgically resected non-small cell lung cancer.

Authors:  Jae Kwang Yun; Geun Dong Lee; Hyeong Ryul Kim; Yong-Hee Kim; Dong Kwan Kim; Seung-Il Park; Sehoon Choi
Journal:  J Thorac Dis       Date:  2019-07       Impact factor: 2.895

3.  Low Hematocrit Is a Strong Predictor of Poor Prognosis in Lung Cancer Patients.

Authors:  Xin Zhang; Fengmin Zhang; Wenbo Qiao; Xiansheng Zhang; Zhefeng Zhao; Mingqi Li
Journal:  Biomed Res Int       Date:  2018-10-17       Impact factor: 3.411

4.  Elevated DKK1 expression is an independent unfavorable prognostic indicator of survival in head and neck squamous cell carcinoma.

Authors:  Haihe Gao; Lisha Li; Mang Xiao; Yongwei Guo; Yi Shen; Lixin Cheng; Ming Tang
Journal:  Cancer Manag Res       Date:  2018-10-30       Impact factor: 3.989

5.  RNSCLC-PRSP software to predict the prognostic risk and survival in patients with resected T1-3N0-2 M0 non-small cell lung cancer.

Authors:  Yunkui Zhang; YaoChen Li; Rongsheng Zhang; Yujie Zhang; Haitao Ma
Journal:  BioData Min       Date:  2019-08-23       Impact factor: 2.522

6.  New TNM staging in lung cancer (8th edition) and future perspectives.

Authors:  José-María Matilla; M Zabaleta; E Martínez-Téllez; J Abal; A Rodríguez-Fuster; J Hernández-Hernández
Journal:  J Clin Transl Res       Date:  2020-09-02

Review 7.  Validation of the 8th lung cancer TNM classification and clinical staging system in a German cohort of surgically resected patients.

Authors:  Samantha Taber; Joachim Pfannschmidt
Journal:  Innov Surg Sci       Date:  2020-08-12

8.  Epigenetic silencing of microRNA-199a-5p promotes the proliferation of non-small cell lung cancer cells by increasing AKAP1 expression.

Authors:  Nengli Yang; Yafeng Liang; Tianqi Zhu; Yanxiao Long; Zhe Chen; Xuezheng Zhang; Liuming Jiang
Journal:  Oncol Lett       Date:  2021-03-31       Impact factor: 2.967

9.  Promoter hypermethylation of CD133/PROM1 is an independent poor prognosis factor for head and neck squamous cell carcinoma.

Authors:  Zele Hu; Huigao Liu; Xinrong Zhang; Bin Hong; Zhenhua Wu; Qun Li; Chongchang Zhou
Journal:  Medicine (Baltimore)       Date:  2020-03       Impact factor: 1.817

10.  Survival Analysis in Single N2 Station Lung Adenocarcinoma: The Prognostic Role of Involved Lymph Nodes and Adjuvant Therapy.

Authors:  Marco Chiappetta; Filippo Lococo; Giovanni Leuzzi; Isabella Sperduti; Emilio Bria; Leonardo Petracca Ciavarella; Felice Mucilli; Pier Luigi Filosso; Giovannibattista Ratto; Lorenzo Spaggiari; Francesco Facciolo; Stefano Margaritora
Journal:  Cancers (Basel)       Date:  2021-03-16       Impact factor: 6.639

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.